

# A rare case of thrombotic thrombocytopenic purpura (TTP) presented with cerebral venous sinus thrombosis

Fawaz Mohammed Alhemaïd, Motaz Gafer Helali, Noha Sulieman

Neuroscience Department, King Fahd Armed Forces Hospital, Jeddah, Saudi Arabia.  
Correspondence to: Motaz Gafer Helali, E-mail: mgmhelali@hotmail.com

Received August 6, 2016. Accepted August 17, 2016

## Abstract

Thrombotic thrombocytopenic purpura (TTP) is a rare blood disorder characterized by thrombotic microangiopathy caused by reduced activity of the Von Willebrand factor-cleaving protease ADAMTS13. A rare case of TTP associated with cerebral venous sinus thrombosis has been reported. A 36-year-old male, who has diabetes and had recent left middle cerebral artery (MCA) infarction, presented to the emergency room with recurrent generalized tonic clonic seizure. Investigations revealed evidence of thrombocytopenia, microangiopathic hemolytic anemia and acute kidney injury. MRV brain showed cerebral venous sinus thrombosis. The association of TTP with cerebral venous sinus thrombosis is extremely rare and worth further studies.

**KEYWORDS:** Thrombotic thrombocytopenic purpura, generalized tonic clonic seizure, cerebral venous sinus thrombosis

## Introduction

Thrombotic thrombocytopenic purpura (TTP) is a rare hematological disorder that proved fatal in most cases if not treated properly. It is more common in adults unlike the closely related disorder, hemolytic uremic syndrome, which is more common in children. Both are characterized by thrombocytopenia and microangiopathic hemolytic anemia. Neurologic abnormalities are characteristic for TTP. In the past, before the availability of plasmapheresis as an effective therapy for TTP, the diagnosis was based on the presence of pentad of microangiopathic hemolytic anemia, thrombocytopenia, neurologic and renal abnormalities as well as fever. Because of the presence of effective treatment now, the need for early recognition has led to less strict diagnostic criteria which allow prompt initiation of therapy.<sup>[1]</sup> In a randomized clinical trial demonstrating the effectiveness of plasma exchange therapy, the presence of microangiopathic hemolytic anemia and thrombocytopenia without recognized alternative cause was sufficient for the diagnosis of TTP.<sup>[2]</sup>

TTP can be inherited or acquired. The incidence of acquired TTP is approximately three cases per one million adults per year, based on data from the Oklahoma TTP-HUS Registry.<sup>[3]</sup>

In a retrospective study, the results showed that posterior reversible encephalopathy syndrome (PRES) was the most common brain imaging abnormality in severe manifestations of TTP. Moreover, it is also found that large infarctions and hemorrhage were infrequent. Hence, abnormal brain neuroimaging does not seem to affect patient outcome, and full neurologic recovery is still possible even in comatose patients with extensive brain abnormalities on MRI.<sup>[4]</sup>

## Case Report

A case of 36-year-old male with known case of DM, HTN and recent ischemic stroke presented to the emergency department with subjective fever at home, vomiting, and recurrent generalized seizure for one day. The patient is also a smoker for several years. The patient has no past history of seizure or family history of epilepsy and was noncompliant with his medications. The patient was admitted in another hospital one month ago and diagnosed as having left middle cerebral artery (MCA) infarction. On examination, patient was awake T = 37.8° C, BP=145/90. The patient had global aphasia and residual right side hemiplegia. Other systems examinations were unremarkable and no evidence of skin rash. Investigations revealed the following ECG: sinus bradycardia with prolonged QT interval. Blood test: platelet = 19 10<sup>9</sup> (was 225 one month ago) Hb =12.4 g/dl, Hct = 36.7, WBC =

### Access this article online

Website: <http://www.ijmsph.com>

DOI: 10.5455/ijmsph.2017.06082016593

Quick Response Code:




13.2, urea = 19.1 mmol/L, Creatinine = 164 umol/L (was normal one month ago), CRP=61.9, blood picture showed schistocytes = 2 + RBG = 18 mmol/L, reticulocytes = 1.4 %, D-dimer = 19.7 mg/L FEU, total bilirubin = 36.1 umol/L, INR = 1, ALT = 32 U/L, conjugated bilirubin = 11.06 umol/L, lactic acid dehydrogenase = 2495 U/L, urine nitrate=positive, urine WBC 12–45 cells, urine RBC more than 56 cells, urine culture = normal flora, blood culture = no growth, HIV test negative.


ECHO: EF 55% with impaired LV relaxation no LV clot and no valvularlesion.

MRI and MRV brain with gadolinium shows left frontoparietal and occipital abnormal signal alteration involving cortical and subcortical area suggestive of left middle cerebral artery MCA infarction (Figure 1). MRA shows left MCA occlusion (Figure 2). MRV shows non opacification of the left transverse sinus with contrast due to underline deep venous sinus thrombosis (Figure 3).


EEG: showed diffuse slowing, however no definite epileptic activity made out (Figure 4).



**Figure 2:** MRA brain with contrast shows occluded left middle cerebral artery (MCA)



**Figure 1:** MRI Brain T2 FLAIR sequence shows left frontoparietal and occipital abnormal signal alteration involving cortical and subcortical area. Consistent with left MCA infarction



**Figure 3:** MRV brain with contrast shows non opacification of the left transverse sinus due to underline deep venous sinus thrombosis



**Figure 4:** EEG showed diffuse slowing however no definite epileptic activity

Patient received antiepileptic medication (NaValporate and levatiracetam) then received plasmapheresis together with pulse steroid therapy followed by rituximab as he developed recurrent relapses. Thereafter, patient regained a normal renal function and platelet count. Then the patient received anticoagulation therapy for his venous sinus thrombosis. Patient was followed by neurology, hematology as well as nephrology teams.

## Discussion

The association of TTP and venous sinus thrombosis represents the unique feature of this case and considered one of the rare atypical presentations of TTP. Atypical presentations of TTP were reported.<sup>[5]</sup> As an example, there have been several reports of patients presenting with neurologic symptoms without evidence of microangiopathic hemolytic anemia (MAHA) and thrombocytopenia who subsequently (within days to weeks) developed typical clinical features of TTP. Therefore, it is possible for neurologic abnormalities to precede hematologic abnormalities. It is assumed that these patients may have specific susceptibility for neurologic abnormalities. It is still unclear whether the initial left MCA ischemic stroke that happened for this patient one month prior to patient's microangiopathic hemolytic anemia is directly related to TTP or not.

Furthermore, patients who have recovered from TTP may have persistent cognitive abnormalities. They often complain of problems of memory, complex attention, and concentration skills as well as rapid language generation. The abnormalities observed in these patients are characteristics of disorders associated with diffuse subcortical microvascular disease.<sup>[6]</sup>

A rare case of superior sagittal sinus thrombosis has been reported in association with Evans syndrome of hemolytic anemia,<sup>[7]</sup> but as far as we know the association of cerebral vein thrombosis with TTP is extremely rare.

## Conclusion

This is a case of thrombotic thrombocytopenic purpura presented with cerebral venous thrombosis complicated with recurrent generalized seizure. Further studies will be required to define the risk for neurological injury in patient who diagnosed with TTP.

## References

1. George JN. Thrombotic thrombocytopenic purpura. *N Engl J Med* 2006 May 4;354 (18):1927–35.
2. Rock GA, Shumak KH, Buskard NA et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. *N Engl J Med* 1991;325:393–7.
3. Reese JA, Muthurajah DS, Kremer Hovinga JA, et al. Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired ADAMTS13 deficiency: comparison of incidence, demographic and clinical features. *Pediatr Blood Cancer* 2013; 60:1676.
4. Burrus TM, Wijidicks EF, Rabinstein AA. Brain lesions are most often reversible in acute thrombotic thrombocytopenic purpura. *Neurology* 2009; 73:66.
5. Sarode R. Atypical presentations of thrombotic thrombocytopenic purpura: *Rev J Clin Apheresis* 2009 Jan 1;24(1):47–52.
6. Kennedy AS, Lewis QF, Scott JG, Kremer Hovinga JA, Lämmle B, Terrell DR, Vesely SK, George JN. Cognitive deficits after recovery from thrombotic thrombocytopenic purpura. *Transfusion* 2009 Jun 1;49(6):1092–101.
7. Shiozawa Z, Ueda R, Mano T, Tsugane R, Kageyama N. Superior sagittal sinus thrombosis associated with Evans' syndrome of haemolytic anaemia. *J Neurol* October 1985;232(5):280–2.

**How to cite this article:** Alhemaïd FM, Helali MG, Sulieman N. A rare case of thrombotic thrombocytopenic purpura (TTP) presented with cerebral venous sinus thrombosis. *Int J Med Sci Public Health* 2017;6:223-225

**Source of Support:** Nil, **Conflict of Interest:** None declared.